IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm.
|
|
- Geraldine Boone
- 5 years ago
- Views:
Transcription
1 IMPLEMENTATION OF A SHARED MEDICAL APPOINTMENT FOR OPIOID OVERDOSE EDUCATION AND NALOXONE KIT TRAINING FOR VETERANS Kristin A. Tallman, Pharm.D, BCPS Clinical Pharmacy Specialist Providence Medical Group April 28, 2017
2 DISCLOSURE Kristin A. Tallman, author of this presentation, has nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation This quality improvement project was performed to improve patient care at the VA Roseburg Healthcare System. It was approved by the Chief of Pharmacy and Pharmacy Therapeutics & Nutrition Committee. As a quality improvement project, this data is not generalizable. The contents of this presentation represent the views of the author; they do not represent the views of the Department of Veterans Affairs or the United States Government.
3 LEARNING OBJECTIVES Review rationale and key recommendations for the outpatient prescribing of naloxone Identify appropriate candidates for a naloxone prescription Discuss benefits of a shared medical appointment (SMA) for providing education to patients
4 PRE-TEST ASSESSMENT 1. Which education topics should be discussed with each patient prescribed a naloxone kit? a) How to determine if a second dose of naloxone is needed b) How to recognize signs and symptoms of an opioid overdose c) When and how to administer naloxone d) All of the above 2. Which of the following patients would benefit most from a naloxone prescription based on their risk factor(s)? a) 66 y.o. male with hypothyroidism prescribed hydrocodone as needed after a motor vehicle accident b) 52 y.o. female prescribed morphine ER with a history of sleep apnea and substance use disorder c) 31 y.o. male with generalized anxiety prescribed hydroxyzine and oxycodone as needed d) 42 y.o. female prescribed oxycodone with a history of diabetes and neuropathy 3. Which of the following is most likely to be observed after implementation of a shared medical appointment? a) Patients feel discouraged and ask fewer questions b) Patient education is provided less efficiently c) Patients report greater satisfaction with care provided d) Patient contact time with their healthcare team is decreased
5 BACKGROUND More than 1,000 people are seen in emergency departments daily for misuse of prescription opioids According to the Centers for Disease Control and Prevention (CDC), in Americans died from an overdose daily Majority of opioid overdose-related deaths occur outside of medical settings, primarily occurring in homes Deaths from prescription opioids has quadrupled since 1999 Centers for Disease Control and Prevention
6 BACKGROUND The World Health Organization, CDC, Substance Abuse and Mental Health Services Administration recommend naloxone as an essential intervention to prevent overdose Naloxone s action is to reverse opioid-mediated effects, which include respiratory depression, CNS depression, and hypotension The VA developed an Opioid Education and Naloxone Distribution (OEND) Program as a harm reduction/risk mitigation strategy Centers for Disease Control and Prevention Substance Abuse and Mental Health Services Administration United States. Department of Veterans Affairs World Health Organization
7 MEDICATION USE EVALUATION Total of 46 prescriptions for naloxone over 12 months (Apr 2015 Mar 2016) Average 4 prescriptions per month Primary Indications For Use Prescription for an opioid, dose <50 mg MED 28% Prescription for an opioid with concomitant benzodiazepine 22% History of, or active, substance use disorder 15% Prescription for an opioid, dose 50 to <100 mg MED 15% Prescription for an opioid, dose 100 mg MED 6.5% No clear indication 6.5% MED = morphine equivalent dose Education of naloxone use and administration was clearly documented in 70% of patients
8 OBJECTIVES AND GOALS Increase access to naloxone kits for patients at risk of opioid overdose Enhance patient and caregiver knowledge about opioid safety and use of naloxone Improve clinic efficiency in providing education to patients about naloxone Develop standardized approach to providing and documenting education
9 SHARED MEDICAL APPOINTMENTS Often referred to as a group visit Includes one or more healthcare professionals Typical length of appointment can be minutes Focused environment for a common condition Benefits include: Increased patient access to care Improved productivity Increased patient satisfaction Edelman D, McDuffie JR, Oddone E, et al Jaber R, Braksmajer A, Trilling JS. J Am Board Fam Med Scott JC, Conner DA, Venohr I, et al. J Am Geriatr Soc
10 CLINIC DESCRIPTION Weekly 60 minute group visit Led by clinical pharmacist Optional minute individual appointment Standardized template to guide education and documentation Patients identified proactively by pharmacy or by provider consult Education Topics Defining an opioid overdose Learning what can cause an overdose Recognizing signs and symptoms of an overdose Learning how to prevent an overdose Steps to take as a first responder Do s and don'ts of responding to an overdose Overview of naloxone and how it works When to use and how to administration naloxone When to give a second dose of naloxone Hands on naloxone kit training
11 EXAMPLES OF CANDIDATES Veterans with high risk medical history Opioid use disorder diagnosis Prescription opioid misuse or injection opioid use History of previous opioid overdose Chronic hepatitis, cirrhosis, alcohol use disorder or other substance use disorder and taking opioid Sleep apnea or pulmonary disease and taking opioid Veterans with high risk medication history An extended-release or longacting prescription opioid 50 mg morphine equivalents per day Prescription benzodiazepine with an opioid Veterans who receive VA or non-va care in these situations HIV education/prevention program (which may provide care to injection opioid users) Syringe access program Emergency departments (e.g. for opioid overdose or intoxication) Inpatient residential care or communitybased treatment for homeless Veterans taking an opioid Primary health care (e.g. follow-up of recent opioid overdose or intoxication) United States. Department of Veterans Affairs
12 OUTCOMES Six month evaluation Total of 42 naloxone fills in 6 months (Apr 2016 Sept 2016) Average 7 prescriptions per month 33 of the 42 patients attended the SMA Improved documentation of education provided; 79% vs 70% All patients who attended the SMA had documentation completed Recent update Total of 41 naloxone fills in 4 months (Nov 2016 Feb 2017) Average 10 prescriptions per month Primary indications for use were opioid dose 100 mg MED (54%) and combination opioid and benzodiazepine (31%)
13 CONCLUSION Implementation of a SMA for opioid and naloxone education increased access to naloxone kits Higher risk patient population targeted ( 100 mg MED) Education was provided efficiently to patients by clinical pharmacists Utilization of a standardized template increased completed documentation Recommendations/Future Steps Utilizing pharmacy students to identify and contact patients categorized as high risk patients Patients prescribed buprenorphine/naloxone for opiate use disorder will be coprescribed a naloxone kit during the induction period
14 POST-TEST ASSESSMENT 1. Which education topics should be discussed with each patient prescribed a naloxone kit? a) How to determine if a second dose of naloxone is needed b) How to recognize signs and symptoms of an opioid overdose c) When and how to administer naloxone d) All of the above
15 POST-TEST ASSESSMENT 1. Which of the following patients would benefit most from a naloxone prescription based on their risk factor(s)? a) 66 y.o. male with hypothyroidism prescribed hydrocodone as needed after a motor vehicle accident b) 52 y.o. female prescribed morphine ER with a history of sleep apnea and substance use disorder c) 31 y.o. male with generalized anxiety prescribed hydroxyzine and oxycodone as needed d) 42 y.o. female prescribed oxycodone with a history of diabetes and neuropathy
16 POST-TEST ASSESSMENT 1. Which of the following is most likely to be observed after implementation of a shared medical appointment? a) Patients feel discouraged and ask fewer questions b) Patient education is provided less efficiently c) Patients report greater satisfaction with care provided d) Patient contact time with their healthcare team is decreased
17 REFERENCES Centers for Disease Control and Prevention. Prescription Drug Overdose in the United States: Fact Sheet Retrieved from: Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain United States, Centers for Disease Control and Prevention. March 18, Retrieved from: Edelman D, McDuffie JR, Oddone E, et al. Shared Medical Appointments for Chronic Medical Conditions: A Systematic Review. Department of Veterans Affairs Health Services Research & Development Service. VA-ESP Project #09-010; Jaber R, Braksmajer A, Trilling JS. Group Visits: A Qualitative Review of Current Research. J Am Board Fam Med. 2006;19(3): Oregon Health Authority. Opiate Overdose Treatment: Naloxone Training Protocol. September 22, Retrieved from: Scott JC, Conner DA, Venohr I, et al. Effectiveness of a Group Outpatient Visit Model for Chronically Ill Older Health Maintenance Organization Members: A 2-year Randomized Trial of the Cooperative Health Care Clinic. J Am Geriatr Soc. 2004;52: Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit. January 15, Retrieved from: United States. Department of Veterans Affairs. Veterans Health Administration. Implementation of Opioid Overdose Education and Naloxone Distribution (OEND) to Reduce Risk of Opioid- Related Death (IL ) Washington DC: Petzel, R. United States. Department of Veterans Affairs. Veterans Health Administration. Recommendations for Issuing Naloxone Rescue for the VA Opioid Overdose Education and Naloxone Distribution (OEND) Program Washington DC: Goodman, F. Wheeler, E., Burk, K., McQuie, H., & Stancliff, S. Guide To Developing and Managing Overdose Prevention and Take-Home Naloxone Projects: Harm Reduction Coalition Retrieved from: World Health Organization. Community Management of Opioid Overdose Retrieved from:
Opioid Overdose Education and Naloxone Distribution
Opioid Overdose Education and Naloxone Distribution Emily Stoukides, PharmD PGY-2 Ambulatory Care Pharmacy Resident Nicole Brunet, PharmD, BCPP Clinical Pharmacy Specialist, Mental Health Disclosures Emily
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationOpioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services
Opioid Safety Initiative Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services 1 2 Opioid Safety Initiative (OSI) Overdose Education and Naloxone Distribution (OEND):
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationTake Home Naloxone: Law Update and Considerations for Pharmacy Professionals
Take Home Naloxone: Law Update and Considerations for Pharmacy Professionals Clint Ross, PharmD, BCPP Clinical Pharmacy Specialist Psychiatry Residency Program Director Psychiatric Pharmacy Medical University
More informationRunning Head: PICOT-D ASSIGNMENT 1. NURS 610: PICOT-D Assignment. Peggie L. Powell. VCU School of Nursing DNP Program
Running Head: PICOT-D ASSIGNMENT 1 NURS 610: PICOT-D Assignment Peggie L. Powell VCU School of Nursing DNP Program PICOT-D ASSIGNMENT 2 PICOT-D Component Component Wording (P)atient population Among providers
More informationPain Management and Safe use of opioids in hospitals. Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN
Pain Management and Safe use of opioids in hospitals Kyoung-Sil Kang, PharmD, BCPS Scott Tam, PharmD Lauve Casimir, RN, MSN Bronx Care Health System Bronx Lebanon Hospital Concourse/ Fulton division, Nursing
More informationTITLE AUTHORS. Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy
TITLE Naloxone Counseling for Harm Reduction and Patient Engagement AUTHORS Lucas G. Hill, PharmD The University of Texas at Austin College of Pharmacy Marianne E. Koenig, PharmD UPMC St. Margaret Family
More informationPrescription Opioid Overdose in Oregon: A public health perspective
Prescription Opioid Overdose in Oregon: A public health perspective Katrina Hedberg, MD, MPH Health Officer & State Epidemiologist Oregon Public Health Division Oregon Health Authority All-Cause Mortality,
More informationManagement of Pain - A Comparison of Current Guidelines
Management of Pain - A Comparison of Current Guidelines The Centers for Disease Control and Prevention (CDC) released a guideline in 2016 regarding the prescribing of opioids for chronic non-cancer pain
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More informationAddressing the Opioid Epidemic in the Veterans Health Administration
Addressing the Opioid Epidemic in the Veterans Health Administration Julie Gochnour, MD Governor s Working Group on Veterans, Service Members, and Their Families May 25, 2017 Overview Epidemiology of the
More informationNorth Dakota Board of Pharmacy
North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives
More informationVeterans Health Administration Pharmacy Benefits Management Academic Detailing Services
Veterans Health Administration Pharmacy Benefits Management Academic Detailing Services Melissa Christopher, Pharm.D. National Director, Academic Detailing Services VACO PBM San Diego, California USA Academic
More informationMainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders
Mainstreaming naloxone rescue kits from harm reduction programs to pharmacies, police and fire responders Alexander Y. Walley, MD, MSc Boston University School of Medicine ThINC Bergen 2015 Conference
More informationOpioid epidemic and PEHP
Opioid epidemic and PEHP Agenda Overview of opioid crisis Utah perspective PEHP: clinical interventions Impact of interventions Why are we here? In the 1990s, the medical establishment came to believe
More informationPractical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
More informationOregon s PDMP: An epidemiological assist tool
Oregon s PDMP: An epidemiological assist tool Todd Beran Center for Prevention and Health Promotion Oregon Health Authority PDMP TTAC Webinar February 13, 2013 1 Acknowledgements Lisa Millet, MSH, Section
More informationWisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline
Wisconsin Opioid Prescribing Guideline Draft Scope and purpose of the guideline: To help providers make informed decisions about acute and chronic pain treatment -pain lasting longer than three months
More informationApproved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina
Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina Robert B. Hanlin, M.D., FAAFP Vice Chair, Medical Staff Affairs Greenville Health System Greenville, SC Disclosures
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 2017 (2017Q4)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT FOURTH QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationNew Guidelines for Opioid Prescribing
New Guidelines for Opioid Prescribing What They Mean for Elders with Chronic Pain Manu Thakral, PhD, ARNP Kaiser Permanente Washington Health Research Institute Kaiser Permanente Washington Health Research
More informationSpotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017
Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial
More informationVeteran s Integrative Pain (VIP) Center: A program for high risk patients on chronic opioids
Veteran s Integrative Pain (VIP) Center: A program for high risk patients on chronic opioids Hunter Holmes McGuire VA Richmond, VA Maggie Roma ANP-BC Clinic Administrative Coordinator Objectives Acknowledge
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2018 (2018Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 218 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationOpiate Use Disorder and Opiate Overdose
Opiate Use Disorder and Opiate Overdose Irene Ortiz, MD Medical Director Molina Healthcare of New Mexico and South Carolina Clinical Professor University of New Mexico School of Medicine Objectives DSM-5
More informationManaged Care Pushes for Safer Opioid Oversight
Page 1 of 6 Clinical AUGUST 11, 2017 Managed Care Pushes for Safer Opioid Oversight High-risk pain Rx eyed Denver Health systems haven t escaped the nation s ongoing opioid crisis, as evidenced by surging
More informationDefining the Role of the Pharmacist in Combatting the Opioid Epidemic
Defining the Role of the Pharmacist in Combatting the Opioid Epidemic Dan Hartung, PharmD, MPH Oregon State University, College of Pharmacy Portland, OR Nicole O Kane, PharmD HeathInsight Oregon Portland,
More informationSyringe Service Programs: Platforms for Engagement. September 28, 2018 Melissa Green, MASW, LSW Harm Reduction Program Manager Columbus Public Health
Syringe Service Programs: Platforms for Engagement September 28, 2018 Melissa Green, MASW, LSW Harm Reduction Program Manager Columbus Public Health Strategy: Syringe Service Programs Harm Reduction focuses
More informationAddiction to Opioids. Marvin D. Seppala, MD Chief Medical Officer
Addiction to Opioids Marvin D. Seppala, MD Chief Medical Officer Mayo Clinic Opioid Conference: Evidence, Clinical Considerations and Best Practice Friday, September 30, 2016 26 y.o. female from South
More informationDepartment of Veterans Affairs Network Policy No.: VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA
Department of Veterans Affairs Network Policy No.: 2014-01 VA Desert Pacific Healthcare Network (VISN 22) Date: September 23, 2014 Long Beach, CA CHRONIC OPIOID USE FOR NON-MALIGNANT PAIN 1. PURPOSE: To
More informationNavigating Pain Management during the Opioid Epidemic: Focus Group Findings
Navigating Pain Management during the Opioid Epidemic: Focus Group Findings David Cameron Oregon Health & Science University Department of Family Medicine, Portland, OR Funding received from AHRQ (5R18HS024227-02)
More informationThere are no financial or other pertinent conflicts of interest to disclose. Learning Objectives: Key Questions To Ask 10/4/2014
Maintaining Patient Safety When Chronic Opioid Therapy Is Prescribed P. David Pacheco, Ph.C, PA-C, CAAAPM Pain Medication Management Specialist Southwest Interventional Pain Specialists, PC 4700 Jefferson
More informationThe Opioid Crisis in Minnesota: On the Ground Approaches. Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP
The Opioid Crisis in Minnesota: On the Ground Approaches Laura Palombi, PharmD, MPH, MAT, AE-C Heather Blue, PharmD, BCPS, BCGP Objectives Describe current pharmacy practices to address the opioid crisis
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More informationThe Population is Abusing Drugs, but are Drugs Abusing Insurance?
Image licensed from Shutterstock The Population is Abusing Drugs, but are Drugs Abusing Insurance? 01/30/2018 Gina C. Guzman, MD, DBIM, FALU, FLMI, VP and Chief Medical Director Tim Morant, FSA, MAAA,
More informationPrescription Monitoring Program (PMP)
06/15/2018 FACT SHEET Implementation of Enacted Prescribing Limits and Requirements and Relevant Opioid Prescribing Laws and Rules Background: The 2016 law (Chapter 488) makes five major changes to opioid
More informationOpioids: What You Should Know About Opioid Prescribing. Denis G. Patterson, DO Nevada State Medical Association October 19, 2016
Opioids: What You Should Know About Opioid Prescribing Denis G. Patterson, DO Nevada State Medical Association October 19, 2016 Contact Information Denis G. Patterson, DO Nevada Advanced Pain Specialists
More informationAN OVERVIEW OF THE PRESENTATION AND TREATMENT OF OPIOID OVERDOSE
AN OVERVIEW OF THE PRESENTATION AND TREATMENT OF OPIOID OVERDOSE Jasmine Carpenter, Pharm. D, BCPS, BCPP Clinical Pharmacy Specialist-PACT Mental Health Veterans Affairs Medical Center, Washington DC OBJECTIVES
More informationNM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 2017 (2017Q3)
NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT THIRD QUARTER OF 217 () Substance Abuse Epidemiology Section Prescription Drug Overdose Prevention Program Injury and Behavioral Epidemiology Bureau
More informationQuality Improvement: Evaluating a Naloxone Program
Oregon Health & Science University OHSU Digital Commons Scholar Archive 6-29-2017 Quality Improvement: Evaluating a Naloxone Program Jennifer Herr Follow this and additional works at: http://digitalcommons.ohsu.edu/etd
More informationAcademic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse. Jill M Williams, MD
Academic Medical School: Implementing Curriculum in Chronic Pain and Opioid Misuse Pain, Pain Management and the Opioid Epidemic Symposium Jill M Williams, MD Professor Psychiatry Director, Division Addiction
More informationStrategies in Managing Opioid and Benzodiazepine Co-Prescribing
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes
More informationSlide 1. Slide 2. Slide 3
Slide 1 Opioid Update: What s Happening at the National, State and Local Level? Susan DeVuyst-Miller, PharmD, AE-C Assistant Professor, Ferris State University Clinical Pharmacist, Cherry Health Services
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationBuilding a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine
Building a Comprehensive, Community-driven Prevention Approach to the Opioid Crisis in Maine Scott M. Gagnon, MPP, PS-C Director, AdCare Educational Institute of Maine, Inc. Co-Chair, Prevention & Harm
More informationPolicy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04
Policy on Pharmacological Therapies Practice Guidance Note Reducing Dosing Errors with Opioid Medicines V04 Date issued Issue 1 Nov 2018 Planned review Nov 2021 PPT-PGN 18 part of NTW(C)38 Pharmaceutical
More informationPharmacist Learning Objectives
Opioid Overdose Education and Naloxone Distribution Keith Thornell, Pharm.D. Clinical Pharmacist Co-Occurring Disorders Pain Clinic NM Veterans Affairs Health Care System richard.thornell@va.gov 1 Pharmacist
More informationMedication Misuse and Abuse: A Growing Epidemic
Medication Misuse and Abuse: A Growing Epidemic Colorado Providers Association Professionalizing Prevention June 19, 2015 Mancia Ko, PharmD, MBA Associate Director, Medical Affairs,, Ameritox Assistant
More informationOpioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose
1 Opioid Review and MAT Clinic Comorbidities Associated with Opioid Overdose March 7, 2018 Learning Objectives Differentiate the medical diagnoses that increase the risk of taking opioids Identify the
More informationOpioid Use in Youth. Amy Yule M.D. March 2,
Opioid Use in Youth Amy Yule M.D. March 2, 2018 An opioid is a substance that acts on opioid receptors Beta-endorphin Endogenous opioids Dynorphin Opiates Natural products of the poppy plant Morphine Heroin
More informationNaloxone HCI 4 mg/0.1. nostril. Repeat after 3 minutes if minimal or no
THE SOUTH CAROLINA BOARD OF MEDICAL EXAMINERS AND THE SOUTH CAROLINA BOARD OF PHARMACY S JOINT PROTOCOL TO INITIATE DISPENSING OF NALOXONE HCI WITHOUT A PRESCRIPTION This joint protocol authorizes any
More informationRevised 9/30/2016. Primary Care Provider Pain Management Toolkit
Revised 9/30/2016 Primary Care Provider Pain Management Toolkit TABLE OF CONTENTS 1. INTRODUCTION Page 1 2. NON-OPIOID SERVICES &TREATMENTS FOR CHRONIC PAIN Page 2 2.1 Medical Services Page 2 2.2 Behavioral
More informationOctober 20, 2016 Scott K. Proescholdbell, MPH. Opioid Overdose and North Carolina s Public Health and Prevention Strategies
October 20, 2016 Scott K. Proescholdbell, MPH Opioid Overdose and North Carolina s Public Health and Prevention Strategies Deaths per 100,000 population Death Rates* for Three Selected Causes of Injury,
More informationFighting the Good Fight: How to Convert Opioids Just Right!
Fighting the Good Fight: How to Convert Opioids Just Right! Tanya J. Uritsky, PharmD, BCPS, CPE Clinical Pharmacy Specialist - Pain Medication Stewardship Hospital of the University of Pennsylvania - Philadelphia,
More informationAN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES
AN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES Elizabeth (Betsy) Crowe, PhD Lucille J. Carriere, PhD Objectives
More informationOpioid Prescription and Illicit Drug Overdoses: On the Rise
Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define
More informationProtocol For: Personally Furnishing Naloxone. Update Log
Protocol For: Personally Furnishing Naloxone Update Log Updated By: Reason for Update: Date: Approved By: K. Benick RN Original draft 6/7/16 Pam Butler Protocol: Personally Furnishing Naloxone_Morrow County
More informationReducing Opioid Deaths: Arizona s Emergency Declaration & Response
Reducing Opioid Deaths: Arizona s Emergency Declaration & Response September 15, 2017 Sheila Sjolander, Assistant Director Arizona Department of Health Services Emergency Declaration On June 5, 2017, Arizona
More informationOpioid Dependence and Buprenorphine Management
Opioid Dependence and Buprenorphine Management Kevin Kapila, MD Fenway Health Medical Director of Behavioral Health Instructor in Medicine Harvard Medical School Learning Objectives Understand the rationale
More informationIdaho DUR Board Meeting Minutes. Committee Member Present: David Agler, M.D., Dawn Berheim, Pharm.D., Perry Brown, M.D., Matthew Hyde, Pharm.D.
Idaho DUR Board Meeting Minutes Date: January 25, 2018 Time: 9am-12:00pm Location: Idaho Medicaid, 3232 Elder Street, Boise, Idaho, Conference Room D-West Moderator: David Agler, M.D. Committee Member
More information8.0 Take Home Naloxone
8.0 Take Home Naloxone 8.1 Population characteristics For the financial year (FY) 2016/17, 721 take home naloxone (THN) kits were issued in the City of Edinburgh. Of the 323 individuals who received naloxone
More informationSix Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents,
Six Years of Opioid-Involved Accidental and Undetermined Fatalities among Connecticut Residents, 2009-2014 Lauretta E. Grau, Russell Skip Barbour, and Shawn M. Lang Background Heroin Deaths FDA efforts
More informationUse of Opioids for Chronic Non Malignant Pain (CNMP)
I. PURPOSE Use of Opioids for Chronic Non Malignant Pain (CNMP) We the Safe Opioid Prescribing and Review Committee (SOPARC) are inspired to support a shift in opioid prescribing that improves clinical
More informationTeaming Up for Safer Pain Management: Strategies for Effective Collaboration
Teaming Up for Safer Pain Management: Strategies for Effective Collaboration Noah Nesin, MD, FAAFP, Vice President of Medical Affairs, Penobscot Community Health Care Felicity Homsted, PharmD, DPLA, Chief
More informationScope of the Opiate Problem 6/5/18. Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond. Overview.
Chronic Pain Management and the Use of Opioid Medications: The CDC Guideline and Beyond David Anisman, MD Medical Director, Farmington Health Center (Primary Care) Associate Medical Director, Community
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationMedical Assisted Treatment. Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center
Medical Assisted Treatment Dr. Michael Baldinger Medical Director Haymarket Center Harborview Recovery Center Current Trends Prescription Drug Abuse/Addiction Non-medical use of prescription pain killers
More informationOPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL
OPIOID USE DISORDER AND THE PSYCHIATRIC EMERGENCY ROOM THE VA CT MODEL Brian Fuehrlein, MD PhD VA Connecticut Healthcare System and Yale University I have no conflicts of interest or relevant financial
More informationOpioid Use: Current Challenges & Clinical Advancements
Opioid Use: Current Challenges & Clinical Advancements Whitney Bergquist, PharmD, MBA, BCPS Acute Care NPPA Conference February 8, 2017 2017 MFMER slide-1 No Disclosures 2017 MFMER slide-2 Objectives Summarize
More informationWorking with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.
Working with People Who Use Drugs in HIV Care Settings August 29, 2017 Workshop C 2:00 3:30 p.m. Working with People Who Use Drugs in HIV Care Settings Facilitator: Liz Hall, CDPH Office of AIDS Matt Curtis,
More informationCDC Guideline for Prescribing Opioids for Chronic Pain
National Center for Injury Prevention and Control CDC Guideline for Prescribing Opioids for Chronic Pain John Halpin, MD, MPH Medical Officer Division of Unintentional Injury Prevention Prescription Drug
More informationAddressing the Opioid Epidemic in Tennessee
Addressing the Opioid Epidemic in Tennessee A Multidisciplinary Approach Melissa McPheeters, PhD, MPH Director, Informatics and Public Health Analytics 26 108 733 *Source: CDC References Centers for
More informationOpioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices
Opioid Safety: Prescribing Guidelines, Quality Measures and Care Coordination Best-Practices August 25, 2017 Presented by Michael Crooks, PharmD. Medication Safety and Care Coordination Task Lead 8/28/2017
More informationTHE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING
THE PROS & CONS OF THE CDC GUIDELINES FOR SAFE OPIOID PRESCRIBING Ernest J Dole, PharmD, PhC, FASHP, BCPS Clinical Pharmacist University of New Mexico Hospitals And Clinical Associate Professor University
More information4/18/2018. Disclosure Statement. Background. Learning Objectives. Background. Background
Disclosure Statement The implementation of a pharmacy run outpatient addiction clinic focusing on patients with high risk for negative outcomes with active alcohol use disorder (AUD) By Jaime Cantu April
More informationBuprenorphine Order Set and Rapid Access Referral. Copyright 2017, CAMH
2 Buprenorphine Order Set and Rapid Access Referral 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives Solution
More informationNaloxone and Combating the Opioid Epidemic
Objectives Naloxone and Combating the Opioid Epidemic Jeff Jacobson PharmD Southpointe Pharmacy Discuss the current opioid crisis Define the role of Naloxone in opioid overdose Analyze the barriers to
More informationChronic Pain: Decreasing Dependence on Opioids
University of Vermont ScholarWorks @ UVM Family Medicine Block Clerkship, Student Projects College of Medicine 2016 Chronic Pain: Decreasing Dependence on Opioids Derek Luzim Follow this and additional
More informationPrescription Drug Misuse/Abuse in Seniors. April Rovero Founder/Executive Director
Prescription Drug Misuse/Abuse in Seniors April Rovero Founder/Executive Director Deaths per 100,000 Population 30 25 Overdose Demographics Drug Poisoning Death Rates by Age: United States (2010) 20 15
More informationMark Edlund, MD, PhD RTI International. Photo courtesy of The Herb Museum, Vancouver, BC
Opioid Use Disorders and Their Treatment Mark Edlund, MD, PhD RTI International Photo courtesy of The Herb Museum, Vancouver, BC Acknowledgements Funded by NIDA R01 DA022560-01 NIDA R01 DA034627 NIDA R01
More informationROOM project Addressing the Opioid Epidemic in the U.P. Presented by; Kevin L. Piggott, MD, MPH May 21, 2018
ROOM project Addressing the Opioid Epidemic in the U.P. Presented by; Kevin L. Piggott, MD, MPH May 21, 2018 REDUCING OPIOID OVERDOSE IN MARQUETTE COUNT Y (ROOM) Funding provided by the CDC to the Michigan
More informationThe Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM
The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions
More informationNew Guidelines for Prescribing Opioids
New Guidelines for Prescribing Opioids Keeping Your Claimants Safe Presented by: Dr. Mitch Freeman, Pharm.D. Chief Clinical Officer, Pharmacy Solutions Agenda The Opioid Challenge Today How We Got Here
More informationArticle #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention. Understanding the Epidemic
Article #2 Prescription Drug Overdose CDC: Centers for Disease Control and Prevention Understanding the Epidemic When the Prescription Becomes the Problem In a period of nine months, a tiny Kentucky county
More informationNaloxone: Preventing Opioid Overdose in the Community. Sharon Stancliff, MD Medical Director Harm Reduction Coalition
Naloxone: Preventing Opioid Overdose in the Community Sharon Stancliff, MD Medical Director Harm Reduction Coalition DISCLOSURES Sharon Stancliff MD has nothing to disclose LEARNING OBJECTIVES 1. Discuss
More informationWalking the Line: Opioid Dose De-escalation
Walking the Line: Opioid Dose De-escalation Courtney Kominek, PharmD, BCPS, CPE Disclosures Axial Healthcare Consultant Daiichi Sankyo Honoraria The views and opinions expressed in this presentation are
More informationOpioid Review and MAT Clinic CDC Guidelines
1 Opioid Review and MAT Clinic CDC Guidelines January 10, 2018 Housekeeping Use chat feature to inform everyone who s at your clinic Click chat on Zoom option bar Chat Everyone the names of those who are
More informationOpioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative
Opioid Guardianship Project: Combating the Opioid Crisis Sarah Derr, PharmD Meg Nugent, MHA, RN Iowa Healthcare Collaborative Objectives Summarize the current crisis at the national and Iowa state level.
More informationOPIOID PRESCRIBING RULES. May 17, 2017 Webinar
OPIOID PRESCRIBING RULES May 17, 2017 Webinar Outline Introduction and Universal Precautions Dr. Levine, Commissioner, Health Department 15 Minutes Acute Pain Dr. Patti Fisher, UVMMC 20 Minutes Chronic
More informationThe Opioid Addiction Emergency In Virginia June 8, 2017
The Opioid Addiction Emergency In Virginia June 8, 2017 Marissa J. Levine, MD MPH State Health Commissioner Virginia Department of Health Chronic Disease of Addiction Definition: A primary, chronic disease
More informationPartnership HealthPlan of California s Managing Pain Safely Program Robert Moore, MD MPH Chief Medical officer Partnership HealthPlan of California
Session L6 This presenter has nothing to disclose It Takes a Village to Curb the Prescription Opioid Epidemic: Partnership HealthPlan of California s Managing Pain Safely Program Robert Moore, MD MPH Chief
More informationCoalition Strategies Across The Continuum of Care
Coalition Strategies Across The Continuum of Care Dorothy J. Chaney M.Ed. CADCA Consultant Building Safe, Healthy, and Drug Free Communities Overview and Objectives: By completing this training participants
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2099-5 Program Prior Authorization/Medical Necessity Buprenorphine Products (Pain Indications) Medication Belbuca (buprenorphine
More information1/30/2017 SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT ACPE PRE-TEST QUESTIONS. I have no declarations.
SEISMIC UPGRADE FOR THE OPIOID PARADIGM SHIFT Traci Hamer, PharmD, MAT Kaiser Permanente Northwest Pain Management Pharmacy Services I have no declarations. ACPE PRE-TEST QUESTIONS True/False: Opioids
More information